{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(9)"],"submitter":["Lorenzoni V"],"funding":["Edwards Lifesciences","Scuola Superiore Sant&apos;Anna"],"pubmed_abstract":["<h4>Objectives</h4>To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk.<h4>Methods</h4>A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I-IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) we"],"journal":["The European journal of health economics : HEPAC : health economics in prevention and care"],"pagination":["1349-1363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8558181"],"repository":["biostudies-literature"],"pubmed_title":["The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups."],"pmcid":["PMC8558181"],"pubmed_authors":["Turchetti G","Saia F","Berti S","Candolfi P","Lorenzoni V","Meucci F","Martinelli GL","Cerillo AG","Barbieri G"],"additional_accession":[]},"is_claimable":false,"name":"The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups.","description":"<h4>Objectives</h4>To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk.<h4>Methods</h4>A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I-IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) we","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-26T02:51:36.333Z","creation":"2022-02-11T12:46:59.989Z"},"accession":"S-EPMC8558181","cross_references":{"pubmed":["34019220"],"doi":["10.1007/s10198-021-01314-z"]}}